Loading...
Loading...
MGNX| Name | Value |
|---|---|
| Revenues | 110.7M |
| Cost of Revenue | 1.9M |
| Gross Profit | 108.8M |
| Operating Expense | 54.6M |
| Operating I/L | 54.2M |
| Other Income/Expense | 2.1M |
| Interest Income | 2.1M |
| Pretax | 56.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 56.3M |
MacroGenics, Inc. is a biopharmaceutical company specializing in antibody-based therapeutics for cancer treatment. Its flagship product, MARGENZA, is approved for metastatic HER2-positive breast cancer. The company's pipeline includes immuno-oncology product candidates such as antibody drug conjugates, monoclonal antibodies, and bispecific molecules targeting various cancers. Additionally, it is developing therapies for autoimmune diseases and type 1 diabetes. MacroGenics generates revenue through the commercialization of MARGENZA and potential future approvals of its pipeline products. The company also engages in collaborations with other biopharmaceutical firms to advance its research and development efforts.
